PET imaging using the iodine-124-labeled antibody called chimeric G250 (124I-cG250) can accurately identify clear-cell renal carcinoma, according to a study by researchers at Memorial Sloan-Kettering Cancer Center in New York City. Findings could lead to an improvement in the clinical management of patients with kidney tumors.
The National Cancer Institute estimates that approximately one person in 7500 in the U.S. will develop some type of renal cell carcinoma each year. A third of them will eventually die from the disease. About 90% of renal metastases, which carry the poorest prognosis, are clear-cell RCCs.
This prospective clinical trial is the first to show that PET with a radiolabeled antibody is sensitive and specific enough to identify this histologic subtype, said principal investigator Dr. Chaitanya Divgi, who is now chief of nuclear medicine and clinical molecular imaging at the University of Pennsylvania.
read complete article
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment